[Analysis of survival in 240 patients with unresectable primary hepatocellular carcinoma treated with hepatic artery chemo-embolization].
The effect of transcatheter hepatic artery chemoembolization (TAE) on hepatocellular carcinoma (HCC) was evaluated. The survival time of 240 patients with unresectable primary HCC who were treated by TAE during the period from Jan. 1987 to Jan. 1995 were followed up. The results showed that in this series the overall 1-, 2-, 3-, 5- and 7-year survival rate was 61.0%, 39.2%, 30.7%, 18.9%, 16.0%, respectively. The survival rate of patients treated with TAE plus hepatectomy at 1, 2, 3, 5 and 7 years was 95.2%, 90.4%, 85.0%, 59.0% and 59.0% respectively, while that in patients treated with TAE in 1, 2, 3, 5, 7 years was 58.1%, 34.0%, 24.4%, 13.7%, 9.1%, respectively. This results indicate that TAE therapy is a treatment of choice for patients with advanced hepatocellular carcinoma.
Cheng
L
L
Department of Gastroenterology, PLA General Hospital, Beijing, China.
Wang
Z
Z
Cai
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
D000970:Antineoplastic Agents